Mutations in the human gene for the low density lipoprotein (LDL) receptors produce the clinical syndrome of familial hypercholesterolaemia (FH).1
These receptors are located in coated pits on the cell surface, bind plasma LDL, and carry it into cells by receptor mediated endocytosis. In patients with FH, the genetically defective receptors cause LDL to accumulate to high levels in plasma, which eventually leads to atherosclerosis.
At least 10 different mutant alleles at the LDL receptor locus can be distinguished through biochemical studies of cultured fibroblasts from FH patients.2 A cDNA clone for the human LDL receptor gene has recently been isolated,3 which enables one to study these receptor defects at DNA level. DNA restriction site polymorphisms (RFLPs) around or within structural genes allow identification of alleles, which can be used to study the association with a disease within a population, or segregation of marker alleles and disease within a family.
Previous studies have shown that a PvuII restriction enzyme polymorphism of the LDL receptor gene can be used to show that alleles of this genetic marker coinherit with familial hypercholesterol- *4 aemia. We The demonstration of only a few genotype and haplotype combinations in the populations can be interpreted as non-random association of the three DNA markers of the LDL receptor gene. One of the haplotypes, PISIN2, shows a significantly higher incidence in the FH group (32% in normocholesterolaemics compared with 54% in hypercholesterolaemics). The predominance of the N2 allele of the NcoI polymorphism in FH subjects is clear in tables 2 and 3.
SEGREGATION OF THE RFLP HAPLOTYPES IN FH FAMILIES
We have used the PvuII, Stul, and NcoI polymorphisms to follow the inheritance of the LDL receptor gene in 27 informative families in which FH occurs. In 17 families (46 normal and 75 affected offspring) the PlSlN2 haplotype and the FH phenotype cosegregated. An example of one extended family is shown in fig 3a. The FH phenotype was associated with the P2S2N1 haplotype in seven informative families, where 38 normal and 46 affected offspring were analysed (example of one family in fig 3b) . The PiSIN1 haplotype has shown association with the FH phenotype in two families (four normal and eight affected offspring) and the P2SlN1 haplotype in only one family (seven normal and eight affected offspring). Table 5 shows the frequencies of the different haplotypes associated with FH in 34 unrelated FH heterozygotes. The FH haplotypes were deduced from the pedigree analyses in the 27 families and from seven patients homozygous for all three RFLPs. In 71% of the FH families studied, the PlS1N2 haplotype cosegregates with the defective gene, while the P2S2N1 haplotype segregates in 20% of families. The PISINI and P2S1N1 haplotypes are associated with the FH phenotype in only 6% and 3% of families studied, respectively. Haplotype analysis alone is not sufficient to distinguish normal from FH chromosomes, since the same haplotypes were found in both the normal and FH populations. This finding is interpreted as an indication that the LDL receptor gene haplotypes were established at a point in evolution before the mutations causing FH. It further implies that the FH mutations evolved independently from one another, suggesting that a particular mutation is likely to be associated with a specific haplotype. Variations at these three polymorphic sites may serve as valuable genetic markers, for the identification of different FR mutations, for population studies, and as a basis for prenatal diagnosis of many FH mutations.
